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Schizophrenia is a chronic mental illness. The long-term
aim of treatment is the re-integration into the community
and this can only be achieved by maintaining patients in
a state of remission for as long as possible. With each suc-
cessive relapse, the patient's long-term prognosis deterio-
rates and previous level of functioning are rarely achieved.
In the case of schizophrenia continuous medications is
the most effective strategy against relapse, while discon-
tinuation of antipsychotic treatment seems to be the most
important predictor of relapse. Although the new genera-
tion of atypical antipsychotics are very effective for a
broader range of psychotics symptoms (negative symp-
toms, cognitive, mood) and are better tolerated (primarily
due to their favorable extrapyramidal side-effects profile)
than conventional agents, the effectiveness of antipsy-
chotic treatment is limited by non-compliance. Lack of
compliance has been shown to highly correlate with
relapse and re-hospitalization. Poor compliance is still a
major issue in the long-term treatment of schizophrenia
as the continuous treatment seem to be the exception
rather than the rule for these patients. Research studies
indicate that several factors influence the treatment com-
pliance and the most important being related to illness
(psychotic symptoms, cognitive dysfunction), side-effects
of medications (mainly extrapyramidal symptoms),
patients (little insight), social and environment issues and
therapists. Pharmacological and psychosocial strategies
can improve medication adherence and optimize long-
term outcome for schizophrenics patients. Conventional
antipsychotics are associated with high 1 year relapse rates
(30–50%), although they are significantly lower in
patients receiving depot formulation. Studies with atypi-
cal antipsychotics showed a lower relapse rates (20–30%).
Combining the benefits of atypical with those of a long-
acting (depot) formulation may further reduce relapse
rates and enhance community re-intergration. Psychoso-
cial interventions targeted specifically to problems of poor
compliance, concrete problems solving, motivational
techniques and psycho-education of patients and families
were found to be the most successful in promoting com-
pliance.
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